Gottlieb's FDA Lights A Fire Under Medtech Policy Activity But Reimbursement Challenges Remain
When it comes to the US regulatory and policy environment in 2017, Donald Trump is the first name one must mention. But Trump's unexpected and unconventional presidency is not necessarily the core driving force behind many significant policy developments of most importance to medtech firms in the past year.
You may also be interested in...
2017 was a watershed year in many respects, politically, economically and commercially for many players in the medtech field. Where will the opportunities lie in 2018, will breakthrough medtech innovation still have a place among providers often riding on fumes when it comes to budgets, and is it all as bad as some would make out?
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?